17 results about "Glyceryl behenate" patented technology

The application relates to the technical field of pharmaceutical preparations, and particularly discloses a propranolol hydrochloride tablet with low N-nitrosopropylol impurity content and a preparation method thereof. The propranolol hydrochloride tablet with low N-nitrosopropylol impurity content comprises the following components in parts by weight: 0.2-0.3 parts of propranolol hydrochloride, 2.0-2.3 parts of mannitol, 0.2-0.3 parts of glycerin behenate and 0.05-0.1 parts of magnesium stearate. In the application, mannitol, glycerin behenate and magnesium stearate are used as excipients, the mannitol, the glycerin behenate and the magnesium stearate all have high fluidity, and the glycerin behenate has lubricating and excipient effects, so that the compression of the tablets is facilitated.

The invention discloses an encapsulated oil-in-water type composition and a preparation method thereof. The encapsulated oil-in-water type composition comprises the following components in percentage by weight: 0.1-1% of retinol; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; the oil-phase thickening agent is selected from one or more of dextrin palmitate, a castor oil / IPDI (isophorone diisocyanate) copolymer, an HDI (hexamethylene diisocyanate) / trihydroxymethyl hexyl lactone cross-linked polymer, glyceryl behenate, a hydrogenated (styrene / butadiene) copolymer and dibutyl lauroyl glutamine; 10%-20% of an oil component, wherein the oil component comprises caprylic acid / capric triglyceride; 0.1%-5% of a rheology modifier; 5-20% of a humectant; and the balance of water. The capsule product has good slow release property. According to the composition disclosed by the invention, high-content addition and high-efficacy performance of the retinol are realized, meanwhile, good formula stability can also be realized, and the problem of skin irritation caused by the retinol is improved.

The invention discloses a brovudine cream for treating herpes zoster and a preparation method of the brovudine cream. Specifically, the invention provides a cream which comprises the following components in percentage by mass: 0.1-5% of bromovudine, 5-45% of an organic solvent, 0.3-10% of an emulsifier, 15-55% of an oil phase matrix and water, the cream is an oil-in-water type cream; and any one of the following conditions is met: (C1) the emulsifier comprises 15-hydroxystearic acid polyethylene glycol ester; (C2) the oil phase matrix comprises glyceryl behenate. The brovudine cream provided by the invention has one or more positive progressive effects of good safety, small side reaction, good stability and good treatment effect.

A solidification and solubilization method for a progesterone self-emulsifying liquid formulation and a progesterone self-emulsifying solid formulation. A curing agent is mixed with a progesterone self-emulsifying liquid formulation, wherein the curing agent comprises one or more of lauroyl polyoxyethylene-32 glyceride, polyoxyethylene-8 glyceryl behenate, polyethylene glycol-32 stearate and stearoyl polyoxyethylene glyceride. The melting point of the progesterone self-emulsifying liquid formulation is increased to above room temperature by means of a specific curing agent, such that the progesterone self-emulsifying liquid formulation is in a solid state at room temperature, thereby obtaining a progesterone self-emulsifying solid formulation; moreover, the drug loading capacity of progesterone is enhanced. The solidification and solubilization method can not only improve the solubility of the progesterone to avoid crystallization and precipitation, and improve the uniformity of the formulation, but also improve the self-emulsifying ability of the progesterone self-emulsifying formulation without affecting the release rate of progesterone in the self-emulsifying formulation.

This invention discloses a guanifacine hydrochloride sustained-release tablet and its preparation method. The method includes placing a granulated / mixed, tableted guanifacine hydrochloride pharmaceutical composition into a hot air device for drying. The hot air device is selected from a coating machine or an oven, and the hot air temperature ranges from 30 to 70°C. After drying, the resulting guanifacine hydrochloride sustained-release tablet has a moisture content ≤4.0% by weight, preferably ≤3.5% by weight. The guanifacine hydrochloride pharmaceutical composition contains guanifacine hydrochloride, lactose, microcrystalline cellulose, hydroxypropyl methylcellulose, methacrylate copolymer, fumaric acid, glyceryl behenate, sodium stearate fumarate, and micronized silica gel. This hot air drying process effectively controls the total impurities of the guanifacine hydrochloride sustained-release tablets to ≤1.0% and the single impurities to ≤0.1%. This process improves the safety and stability of the drug, is easy to operate, and is suitable for commercial production.

The application discloses a composition with the effect of auxiliary treatment of arthritis and a preparation method and application thereof, and the composition comprises the following preparation raw materials in parts by weight: non-denatured type II collagen 5-15 parts, curcuma longa extract 56.8-100 parts, frankincense extract 18.7-39.8 parts, sophora flower bud extract 15-28.5 parts, chondroitin sulfate 20-30 parts, glyceryl behenate 15-25 parts, chitosan 3-7.5 parts, sodium deoxycholate 3-8 parts, polyethylene glycol-15 hydroxystearate 5-15 parts, anti-knotting agent 1-3 parts, curing agent 5-15 parts and filling agent 15-25 parts. The application can treat arthritis through the trinity of immune-mechanical-metabolic pathways, and the effect is remarkable and fast, and has a certain residual effect.

The invention discloses a 1-(5-oxohexyl) theobromine sustained-release tablet, the 1-(5-oxohexyl) theobromine sustained-release tablet is composed of a tablet core and a sustained-release coating layer, the tablet core (based on the total weight of the tablet core) is prepared from the following components in parts by weight: 360-450 parts of 1-(5-oxohexyl) theobromine, 50-200 parts of a skeleton sustained-release material, 5-15 parts of an adhesive and 5-10 parts of a lubricant, the matrix sustained-release material is selected from glyceryl behenate and / or polyoxyethylene, preferably, the matrix sustained-release material is selected from glyceryl behenate and polyoxyethylene, the weight ratio of glyceryl behenate to polyoxyethylene is (0.5-2): 1, and the adhesive is prepared into a 95% ethanol solution of 5% povidone K30.

The invention relates to the technical field of high polymer materials, and particularly discloses a hydrophobic controlled-release coating material and a preparation method thereof.The hydrophobic controlled-release coating material comprises a material P and a material I according to the mass ratio of 100: 70-110; the material P is prepared from the following components in parts by mass: 15 to 55 parts of modified recycled regenerated oil, 10 to 30 parts of dicarboxylic acid, 5 to 20 parts of propylene glycol, 10 to 50 parts of polyhydric alcohols, 1 to 3 parts of amine catalysts, 2 to 4 parts of amino acid derivatives and 1 to 3 parts of modified starch; the material I is prepared from the following components in parts by mass: 1 to 3 parts of glyceryl behenate and 10 to 14 parts of vegetable oil-based isocyanate; hydrogenated modified recycled regenerated oil is used as a base material to provide a long-chain hydrophobic skeleton and active carboxyl, glyceryl behenate provides a crystallization hydrophobic micro-area, and an amine catalyst and an amino acid derivative cooperate to reduce reaction activation energy; through hydrophobic network construction, cross-linking enhancement and degradation regulation, a coating structure with high hydrophobicity and precise controlled release is formed; the material is degradable, does not pollute soil, has good hydrophobicity, and can effectively control the dissolution rate of the chemical fertilizer.

The application discloses a solid pharmaceutical composition of meloxicam benzene sulfonic acid, a preparation and a preparation method thereof. The solid pharmaceutical composition comprises meloxicam benzene sulfonic acid, and further comprises L-tartaric acid, ascorbic acid palmitate and a non-ionic ester compound selected from at least one of hydrogenated castor oil and glycerol behenate. The solid pharmaceutical composition of meloxicam benzene sulfonic acid has the stability obviously superior to that of the prior art, and the dissolution performance of the solid preparation is excellent, due to the combination of L-tartaric acid, ascorbic acid palmitate and the non-ionic ester compound selected from at least one of hydrogenated castor oil and glycerol behenate, and the synergistic effect of the three.

The application discloses a reba piate tablet and a preparation method thereof. The tablet comprises reba piate, a carrier material, a filler, a binder, a disintegrant, a lubricant and pharmaceutically acceptable excipients. The carrier material is glyceryl behenate and poloxamer copolymer. The reba piate tablet of the application avoids the increase of impurities in a high-temperature and high-humidity environment, reduces the agglomeration of the raw drug caused by static electricity, adjusts the release rate of the reba piate tablet, and has a simple preparation process and is suitable for industrial mass production.

The invention discloses an oral solid preparation of melogabalin benzene sulfonate, which comprises melogabalin benzene sulfonate, a sugar alcohol filler, a lubricant and a disintegrating agent, and the lubricant is a combination of glyceryl behenate and other lubricants. The other lubricant is selected from one or more of stearic acid, sodium lauryl sulfate, magnesium lauryl sulfate, magnesium aluminum metasilicate, magnesium stearate and sodium stearyl fumarate. According to the present invention, the growth change of the related substances in the melogabalin besylate preparation is researched, the prescription of the oral solid preparation is optimized, and the fact that the glyceryl behenate can significantly improve the stability of the melogabalin besylate preparation is accidentally found, and the preparation method is suitable for various preparation processes, and is more suitable for industrial production.

Mascara compositions with improved aesthetics are provided. Such compositions generally include a plurality of waxes including sunflower seed wax and a plurality of behenates including tribehenin and behenyl behenate. The plurality of waxes may include the sunflower seed wax, the tribehenin, the behenyl behenate, and at least one additional wax. The plurality of waxes may be present in a total amount of about 5% to about 35% by weight of the mascara composition. The combined total amount of sunflower seed wax, tribehenin, and behenyl behenate may be about 5% to about 20% by weight of the composition. The mascara composition may optionally include no more than about 10% water, such as about 2% to about 7%, by weight of the mascara composition.

This invention discloses a method for synergistic moisture-proof and flavor-masking coating of traditional Chinese medicine granules, belonging to the field of pharmaceutical formulation technology. The method includes: S1, obtaining porous starch by enzymatic hydrolysis, ferric chloride complexation, and integrated twin-screw extrusion-enzymatic hydrolysis of corn starch, followed by surface ammoniation modification with 3-aminopropyltriethoxysilane and then mixing and adsorbing with traditional Chinese medicine granules to obtain granules covered with a sacrificial inner layer; S2, alternately coating the granule surface with sodium carboxymethyl cellulose and poly-L-arginine through layer-by-layer self-assembly to form a composite intermediate layer; S3, in-situ coordination polymerization of tannic acid and ferric chloride on the granule surface to form a polymer coating layer; S4, freezing the granules and then using a mixture of behenicol glyceryl ester and cocoa butter as the hot-melt coating material, followed by fluidized bed hot-melt coating. This invention solves the problems of the prior art, such as the separation of moisture-proof and flavor-masking functions, easy escape of volatile oils, and insufficient coating density. The resulting granules have low moisture absorption, high volatile oil retention, long-lasting flavor masking, and precise pH-responsive drug release.

This invention discloses a squalane lip essence oil and its preparation process, comprising the following raw material components: Phase A: tridecyl trimellitate; diisostearyl malate; ethylhexyl palmitate; 972 hydrogen powder; Phase B: glyceryl behenate / eicosadecanate; polyisobutylene; Phase C: hydrogenated (styrene / isoprene) copolymer / pentaerythritol tetra(bis-tert-butylhydroxyhydrogenated cinnamic acid) ester; plant squalane; camellia seed oil; shea butter; avocado oil; baobab oil; comfrey oil; vitamin E acetate; Phase D: pigment; The lip essence oil of this invention can significantly moisturize and nourish, and has repairing, anti-inflammatory and soothing effects on the lip skin.

The invention belongs to the technical field of cosmetics, and particularly relates to soothing cream containing skin-touching oil-melting particles as well as a preparation method and application of the soothing cream. The soothing cream comprises water phase gel and oil phase particles suspended in the water phase gel, the oil phase particles are prepared from the following components in parts by weight: 0.8 to 4 parts of squalane, 0.3 to 3 parts of behenyl alcohol, 0.3 to 3 parts of meadowfoam seed oil, 0.1 to 1 part of polydimethylsiloxane, 0.05 to 1 part of glyceryl behenate, 0.1 to 1 part of stellaria lutescens palm seed grease and 0.01 to 0.1 part of polyacrylate cross-linked polymer-6. The technical bottleneck of a traditional dosage form is broken through, the fresh gel skin feeling and the long-acting sealing effect of grease are organically combined, no sticky burden exists in the using process, the skin feeling is light and comfortable, meanwhile, oil-phase particles are immediately melted when making contact with the skin, effective components can be rapidly released, a long-acting moisturizing repairing barrier is formed, the relieving and moisturizing effect is remarkably improved, and the moisturizing effect is good. The problems of skin dryness, discomfort and the like are effectively improved.

The invention discloses a preparation method of an Azimine hydrochloride tablet, and belongs to the technical field of medicines, the specific preparation method comprises the following steps: mixing Azimine hydrochloride, mannitol, microcrystalline cellulose, polyvinylpolypyrrolidone and fumaric acid at a low speed to obtain premixed dry powder; adding the premixed dry powder into a double-screw hot-melt extruder, adding the standby glyceryl behenate at the same time, extruding to obtain an extrudate, cooling the extrudate, and cutting the extrudate into columnar particles through a screen; transferring the particles into a fluidized bed for cold air curing to obtain cured particles; mechanically finishing the cured particles through a screen, adding colloidal silicon dioxide and magnesium stearate into the cured particles, and mixing to obtain particles to be pressed; and tabletting the to-be-pressed particles by using a rotary tablet press to finally obtain the Azimine hydrochloride tablet. Through an anhydrous melting granulation process and a specific auxiliary material system, the stability, the dissolution performance and the mechanical strength of the medicine are remarkably improved.

The present invention provides a stable emulsified composition. An emulsion composition containing: (A) an oily component; (B) 40% by mass or more of one or more substances selected from a polyhydric alcohol having 3-5 carbon atoms and a polyethylene glycol; (C) one or more substances selected from the group consisting of polyacrylamide compounds and polyvinylpyrrolidone; (D) 0-15% by mass of water; and (E) at least one substance selected from the group consisting of PEG-20 phytosterol, polyoxyethylene eicosyl ether, glyceryl behenate, and polyglycerol-6 octastearate.